Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shattuck Labs, Inc.STTK · Entity 5224 | Chief Technical Officer | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shattuck Labs, Inc.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,533 |
Ending reported balance
After 2026-07-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-02 · Exercise / conversion · Acquired 410 · Balance 86,790 Row 2 · 2026-07-02 · Sale · Disposed 410 · Balance 86,380 F1: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-07-06 · Exercise / conversion · Acquired 12,153 · Balance 98,533 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.57 · Expires 2033-01-25 | Direct | 26,293 |
Reported balance
After 2026-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-02 · Exercise / conversion · Disposed 410 · Balance 26,293 F3: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.57 · Expires 2033-01-25 | Direct | 14,140 |
Reported balance
After 2026-07-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-06 · Exercise / conversion · Disposed 12,153 · Balance 14,140 F3: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 7, 2026 23:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,153 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001193125-26-297768 · ownership.xml · derivative · entry 5 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,140 Underlying: Common Stock · 12,153 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 23:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 12,153 | $3.57 | $43,386.21 |
DisclosureSEC source: 0001193125-26-297768 · ownership.xml · nonDerivative · entry 3 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 23:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 410 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001193125-26-297768 · ownership.xml · derivative · entry 4 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,293 Underlying: Common Stock · 410 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 23:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 410 | $7.01 | $2,874.10 |
DisclosureSEC source: 0001193125-26-297768 · ownership.xml · nonDerivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,380 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 23:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 410 | $3.57 | $1,463.70 |
DisclosureSEC source: 0001193125-26-297768 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 00:17 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001193125-26-295150 · ownership.xml · derivative · entry 6 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,703 Underlying: Common Stock · 100 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 00:17 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 100 | $7.07 | $707.00 |
DisclosureSEC source: 0001193125-26-295150 · ownership.xml · nonDerivative · entry 4 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,380 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 00:17 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 100 | $3.57 | $357.00 |
DisclosureSEC source: 0001193125-26-295150 · ownership.xml · nonDerivative · entry 3 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 00:17 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,365 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001193125-26-295150 · ownership.xml · derivative · entry 5 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,803 Underlying: Common Stock · 23,365 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 00:17 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 23,365 | $7.08 | $165,424.20 |
DisclosureSEC source: 0001193125-26-295150 · ownership.xml · nonDerivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,380 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 00:17 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 23,365 | $3.57 | $83,413.05 |
DisclosureSEC source: 0001193125-26-295150 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2026 Filed May 21, 2026 21:01 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionWarrants (Right to Buy) · Derivative | 5,122 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-26-234774 · ownership.xml · derivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| May 21, 2026 Filed May 21, 2026 21:01 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 5,122 | $1.08 | $5,555.32 |
DisclosureSEC source: 0001193125-26-234774 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,380 Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,032 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001193125-26-224686 · ownership.xml · derivative · entry 3 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,168 Underlying: Common Stock · 2,032 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 2,032 | $7.01 | $14,244.32 |
DisclosureSEC source: 0001193125-26-224686 · ownership.xml · nonDerivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,258 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2026 Filed May 15, 2026 00:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 2,032 | $3.57 | $7,254.24 |
DisclosureSEC source: 0001193125-26-224686 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:48 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock · Derivative | 315,500 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-011847 · ownership.xml · derivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,500 Underlying: Common Stock · 315,500 shares Expires 2036-01-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 315,500 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantWarrants (Right to Buy) · Derivative | 5,122 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-25-189084 · ownership.xml · derivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,122 Underlying: Common Stock · 5,122 shares Expires not disclosed F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F3 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F3 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 5,122 | $0.87 | $4,444.36 |
DisclosureSEC source: 0001193125-25-189084 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,258 F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · balance_after: Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on February 15, 2025 and 2,000 shares acquired by the Reporting Person under the ESPP on August 15, 2025. Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 23:13 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock · Derivative | 165,200 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000950170-25-010013 · ownership.xml · derivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,200 Underlying: Common Stock · 165,200 shares Expires 2035-01-28 F2 · derivative.exercise_date: This option represents a right to purchase a total of 165,200 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 23:13 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,261 | $1.16 | $2,622.76 |
DisclosureSEC source: 0000950170-25-010013 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,536 F1 · balance_after: Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on February 14, 2024 and 600 shares acquired by the Reporting Person under the ESPP on August 14, 2024. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 4,830 | $1.19 | $5,747.70 |
DisclosureSEC source: 0000950170-25-004930 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,597 Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 2,290 | $9.99 | $22,877.10 |
DisclosureSEC source: 0000950170-24-009379 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,427 Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:42 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 66,850 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-24-004670 · ownership.xml · derivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,850 Underlying: Common Stock · 66,850 shares Expires 2034-01-10 F3 · derivative.exercise_date: This option represents a right to purchase a total of 66,850 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2024 Filed Jan 16, 2024 21:42 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 33,425 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-004670 · ownership.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,717 F1 · shares: Consists of 33,425 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on each of February 14, 2023 and August 14, 2023. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 52,200 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000899243-23-002887 · doc4.xml · derivative · entry 2 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,200 Underlying: Common Stock · 52,200 shares Expires 2033-01-25 F2 · derivative.exercise_date: This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 26,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002887 · doc4.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,092 F1 · shares: Consists of 26,100 restricted stock units, which will vest in four equal annual installments beginning on January 25, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:11 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Tax withholdingCommon Stock | 1,933 | $3.03 | $5,856.99 |
DisclosureSEC source: 0000899243-23-001682 · doc4.xml · nonDerivative · entry 1 Shukla Abhinav A. · CIK 0001923377 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,992 F1 · balance_after: Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.